Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
511523 VEERHEALTH

Veerhealth Care Share Price

 

 

Veerhealth Care live price: ₹20.6. It opened at ₹20 vs previous close ₹20; intraday high/low: ₹21/₹20. The 50 & 200 DMA stand at ₹19.91/₹19.04.

Veerhealth Care Performance

  • Today's Low
  • ₹20
  • Today's High
  • ₹21
  • 52 Week Low
  • ₹12
  • 52 Week High
  • ₹24
  • Open Price₹20
  • Previous Close₹20
  • Volume33,071
  • 50 DMA₹19.91
  • 100 DMA₹19.46
  • 200 DMA₹19.04

Veerhealth Care Chart

Investment Returns

  • Over 1 Month + 2.79%
  • Over 3 Month + 18.53%
  • Over 6 Month + 14.38%
  • Over 1 Year + 45.79%

Smart Investing Starts Here Start SIP with Veerhealth Care for Steady Growth!

Invest Now

Veerhealth Care Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 51.6
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 41
  • P/B Ratio
  • 1.8
  • Average True Range
  • 0.81
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.12
  • RSI
  • 53.84
  • MFI
  • 44.87

Veerhealth Care Financials

Veerhealth Care Technicals

EMA & SMA

Current Price
₹20.60
+ 0.17 (0.83%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹20.25
  • 50 Day
  • ₹19.91
  • 100 Day
  • ₹19.46
  • 200 Day
  • ₹19.04

Resistance and Support

20.36 Pivot Speed
  • R3 21.67
  • R2 21.21
  • R1 20.82
  • S1 19.97
  • S2 19.51
  • S3 19.12

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Veerhealth Care has an operating revenue of Rs. 21.34 Cr. on a trailing 12-month basis. An annual revenue growth of 22% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 1% is fair but needs improvement. The company has a reasonable debt to equity of 19%, which signals a healthy balance sheet. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 46 which is a POOR score indicating inconsistency in earnings, a RS Rating of 80 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 56 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Veerhealth Care Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-03-28 Preferential Issue of shares Inter alia, to consider 1. Proposal for raising of funds by way of issue of one or more instruments including equity shares/convertible securities either by way of Preferential Issue or any other mode issue in the ratio of 1:1 of Rs. 10/-.
2026-02-14 Quarterly Results
2025-11-12 Quarterly Results
2025-08-12 Quarterly Results & A.G.M.
2025-05-30 Audited Results & Final Dividend
Date Purpose Remarks
2023-09-22 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Veerhealth Care F&O

Veerhealth Care Shareholding Pattern

31.5%
54.27%
14.23%

Veerhealth Care FAQs

Veerhealth Care share price is ₹20 As on 29 April, 2026 | 10:43

The Market Cap of Veerhealth Care is ₹41.2 Cr As on 29 April, 2026 | 10:43

The P/E ratio of Veerhealth Care is 51.6 As on 29 April, 2026 | 10:43

The PB ratio of Veerhealth Care is 1.8 As on 29 April, 2026 | 10:43

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23